FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034608764> ?p ?o ?g. }

• W2034608764 endingPage "2233" @default.
• W2034608764 startingPage "2224" @default.
• W2034608764 abstract "Abstract Objective Treatment of ankylosing spondylitis (AS) with infliximab, an anti–tumor necrosis factor α monoclonal antibody, was shown to be efficacious in patients with active disease during a 3‐month treatment period. The purpose of this study was to evaluate the efficacy and safety of infliximab treatment of AS for a 1‐year period. Methods This study was an open, observational, extension study of a 3‐month, randomized, placebo‐controlled trial. All patients who had tolerated infliximab (infliximab/infliximab group) or placebo (placebo/infliximab 12‐week crossover group) therapy for 3 months entered the open extension trial (n = 65). Infliximab was administered at a dosage of 5 mg/kg every 6 weeks after the induction phase (weeks 0, 2, and 6). The primary end point was a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Results At week 54, a total of 54 of the 69 patients (78%) continued to take infliximab. The intent‐to‐treat primary efficacy analysis at week 54 showed that 47% of patients in the infliximab/infliximab group (95% confidence interval 31–63) and 51% of the patients in the placebo/infliximab group (95% confidence interval 36–67) achieved 50% improvement in BASDAI scores. In the analysis of those who completed the study, the mean BASDAI scores improved between weeks 0 and 54 in both treatment groups: from 6.6 to 2.4 in the infliximab/infliximab group and from 6.3 to 2.6 in the placebo/infliximab group. The dosage of nonsteroidal antiinflammatory drugs was reduced in ∼70% of the patients. There were significant improvements in measures of functioning, metrologic parameters, and quality of life. Between weeks 12 and 54, a total of 4 patients had serious adverse events that were possibly related to infliximab and resulted in their discontinuing the study. Conclusion Infliximab therapy in AS patients resulted in a rapid and significant improvement in BASDAI scores (>50% improvement) and a durable response for 1 year. The safety profile of infliximab in AS was comparable to that observed in the postmarketing experience for the approved indications." @default.
• W2034608764 created "2016-06-24" @default.
• W2034608764 creator A5001461822 @default.
• W2034608764 creator A5011323027 @default.
• W2034608764 creator A5011554462 @default.
• W2034608764 creator A5012794658 @default.
• W2034608764 creator A5019710723 @default.
• W2034608764 creator A5031406053 @default.
• W2034608764 creator A5032375376 @default.
• W2034608764 creator A5035876758 @default.
• W2034608764 creator A5044290696 @default.
• W2034608764 creator A5054732492 @default.
• W2034608764 creator A5060526475 @default.
• W2034608764 creator A5076851275 @default.
• W2034608764 creator A5081920237 @default.
• W2034608764 creator A5085745432 @default.
• W2034608764 date "2003-08-01" @default.
• W2034608764 modified "2023-10-13" @default.
• W2034608764 title "Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial" @default.
• W2034608764 cites W1965212418 @default.
• W2034608764 cites W1966756689 @default.
• W2034608764 cites W1973248624 @default.
• W2034608764 cites W1975545950 @default.
• W2034608764 cites W1979377048 @default.
• W2034608764 cites W1991274790 @default.
• W2034608764 cites W1999404885 @default.
• W2034608764 cites W2000500639 @default.
• W2034608764 cites W2018697945 @default.
• W2034608764 cites W2022917163 @default.
• W2034608764 cites W2026258433 @default.
• W2034608764 cites W2030187620 @default.
• W2034608764 cites W2048468219 @default.
• W2034608764 cites W2060293635 @default.
• W2034608764 cites W2076276957 @default.
• W2034608764 cites W2091239293 @default.
• W2034608764 cites W2091452114 @default.
• W2034608764 cites W2112391397 @default.
• W2034608764 cites W2115734700 @default.
• W2034608764 cites W2127711040 @default.
• W2034608764 cites W2133744666 @default.
• W2034608764 cites W2152773041 @default.
• W2034608764 cites W2165062595 @default.
• W2034608764 cites W2171341132 @default.
• W2034608764 cites W2319957449 @default.
• W2034608764 cites W4292806894 @default.
• W2034608764 doi "https://doi.org/10.1002/art.11104" @default.
• W2034608764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12905476" @default.
• W2034608764 hasPublicationYear "2003" @default.
• W2034608764 type Work @default.
• W2034608764 sameAs 2034608764 @default.
• W2034608764 citedByCount "234" @default.
• W2034608764 countsByYear W20346087642012 @default.
• W2034608764 countsByYear W20346087642013 @default.
• W2034608764 countsByYear W20346087642014 @default.
• W2034608764 countsByYear W20346087642015 @default.
• W2034608764 countsByYear W20346087642016 @default.
• W2034608764 countsByYear W20346087642017 @default.
• W2034608764 countsByYear W20346087642018 @default.
• W2034608764 countsByYear W20346087642019 @default.
• W2034608764 countsByYear W20346087642020 @default.
• W2034608764 countsByYear W20346087642021 @default.
• W2034608764 countsByYear W20346087642022 @default.
• W2034608764 countsByYear W20346087642023 @default.
• W2034608764 crossrefType "journal-article" @default.
• W2034608764 hasAuthorship W2034608764A5001461822 @default.
• W2034608764 hasAuthorship W2034608764A5011323027 @default.
• W2034608764 hasAuthorship W2034608764A5011554462 @default.
• W2034608764 hasAuthorship W2034608764A5012794658 @default.
• W2034608764 hasAuthorship W2034608764A5019710723 @default.
• W2034608764 hasAuthorship W2034608764A5031406053 @default.
• W2034608764 hasAuthorship W2034608764A5032375376 @default.
• W2034608764 hasAuthorship W2034608764A5035876758 @default.
• W2034608764 hasAuthorship W2034608764A5044290696 @default.
• W2034608764 hasAuthorship W2034608764A5054732492 @default.
• W2034608764 hasAuthorship W2034608764A5060526475 @default.
• W2034608764 hasAuthorship W2034608764A5076851275 @default.
• W2034608764 hasAuthorship W2034608764A5081920237 @default.
• W2034608764 hasAuthorship W2034608764A5085745432 @default.
• W2034608764 hasBestOaLocation W20346087641 @default.
• W2034608764 hasConcept C126322002 @default.
• W2034608764 hasConcept C141071460 @default.
• W2034608764 hasConcept C142724271 @default.
• W2034608764 hasConcept C168563851 @default.
• W2034608764 hasConcept C17991360 @default.
• W2034608764 hasConcept C204787440 @default.
• W2034608764 hasConcept C27081682 @default.
• W2034608764 hasConcept C2776260265 @default.
• W2034608764 hasConcept C2777138892 @default.
• W2034608764 hasConcept C2777402515 @default.
• W2034608764 hasConcept C2777453003 @default.
• W2034608764 hasConcept C2777575956 @default.
• W2034608764 hasConcept C2779650986 @default.
• W2034608764 hasConcept C71924100 @default.
• W2034608764 hasConceptScore W2034608764C126322002 @default.
• W2034608764 hasConceptScore W2034608764C141071460 @default.
• W2034608764 hasConceptScore W2034608764C142724271 @default.
• W2034608764 hasConceptScore W2034608764C168563851 @default.
• W2034608764 hasConceptScore W2034608764C17991360 @default.

• next